Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28348331 | 0.84 | CA12 (0.30) | — | |
| SCHEMBL3074957 | 0.76 | ALOX5 (0.37) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL29664451 | 0.74 | NISCH (0.32) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL1491185 | 0.73 | ALOX5 (0.32) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL1871103 | 0.73 | MEN1 (0.34) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL5181282 | 0.73 | TSHR (0.34) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL2075819 | 0.73 | ALOX5 (0.35) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL1493437 | 0.73 | MEN1 (0.34) | NISCHMEN1TP53MAPTTSHR | |
| SCHEMBL30417860 | 0.73 | AHR (0.33) | AHRNISCHMEN1TP53MAPT | |
| SCHEMBL15284929 | 0.73 | PTGS1 (0.33) | NISCHMEN1TP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | claimed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-110770213-B | Sulfurized benzoxazines for use in the synthesis of polybenzoxazines | 米其林集团总公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-110770314-B | Metal or metallized reinforcement having a surface coated with a cured polybenzoxazine | 米其林集团总公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-110770213-A | Sulfurized benzoxazines for use in the synthesis of polybenzoxazines | 米其林集团总公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110770314-A | Metal or metallized reinforcement having a surface coated with a cured polybenzoxazine | 米其林集团总公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | AHR 1996/4885NISCH 3896/4885MEN1 3423/4885 |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | AHR 619/4885NISCH 1608/4885MEN1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.